Treating Alzheimer with a skin patch

“Exelon Patch”, developed by Novartis is the first skin patch to treat patients with mild to moderate Alzheimer disease. The new therapy that has already been approved by the FDA, is said to be more compliant for it causes less incidents of nausea and vomiting.

Photo: Treating Alzheimer with a skin patch
The FDA also approved the Exelon Patch for the treatment of patients with mild to moderate Parkinson´s disease dementia, a common disorder that affects about 20 % of Parkinson patients.
 
Exelon Patch is a transdermal patch which can be applied to the back, the chest or the upper arm of the patient and supplies the organism with a steady bloodstream level of the drug rivastigmine for 24 hours. This method extends the drug´s tolerability and its effectiveness over a wider range of patients, e.g. those who are not able to take the oral capsule version because of the increased prevalence of gastrointestinal side effects: Due to a study the patch version resulted in three times fewer incidents of nausea and vomiting compared to the oral capsule.
 
The new product should be available in US pharmacies soon. It was also submitted for approval in the European Union.
 
Dieser Artikel ist auch auf Deutsch vorhanden, bitte klicken Sie hier, um ihn zu lesen!

10.07.2007

More on the subject:
Read all latest stories

Related articles

Photo

Temperature range from 0°C to -85°C

Ultra-freezers for safe vaccine and sample storage

Temperature control equipment and systems company Lauda is expanding its portfolio with its new Versafreeze product line. This consists of high-quality ultra-freezers which have been optimized for…

Photo

'Vaccelerate' cooperation

Building a Covid-19 vaccine network across Europe

The European Commission has launched a contingency plan to meet the challenge of the various mutations of the coronavirus. Karolinska Institutet and Karolinska University Hospital are contributing to…

Photo

From the brain to the joints

Common anti-depressant could also treat osteoarthritis

Osteoarthritis affects more than 30 million adults and is the fifth-leading cause of disability in the United States. In a new study, scientists have discovered the cellular pathway that leads to the…

Subscribe to Newsletter